Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'

Key Points

  • Antimicrobial pharmacodynamics attempts to link measures of drug exposure to the observed effect. This differs from other areas of pharmacodynamics because the main indicator of effect and the site of action of the drug is the organism that causes the pathological process.

  • Understanding antimicrobial pharmacodynamics requires the acceptance of four important ideas. First, the drug exposure achieved with a fixed drug dose varies greatly in the infected population of interest. Second, the shape of the concentration–time curve can sometimes affect the outcome. Third, only non-protein-bound drug is microbiologically active. Finally, as the measure of potency increases, the effect any fixed drug dose will cause decreases.

  • All these ideas can be integrated by use of the Monte Carlo simulation to determine the potential use of a drug and dose for the intended population and to estimate susceptibility breakpoints.

  • These techniques can also be used to help suppress the amplification of resistant subpopulations by identifying the drug exposure that will cause this effect and then evaluating the use of different doses for attaining the exposure target in the population of interest.

  • These ideas can be transferred to the clinical arena. The use of optimal sampling techniques allows informative times for blood sample acquisition to be identified. Population modelling followed by Bayesian estimation allows robust estimation of the exposure achieved in a specific patient. Exposure measures relative to the MIC of the pathogen (peak/MIC ratio, AUC/MIC ratio and time > MIC) can then be linked to the desired clinical or microbiological outcome through common statistical techniques, such as logistic regression analysis, classification and regression tree (CART) analysis and Cox proportional hazards modelling.


Antimicrobial pharmacodynamics is the discipline that integrates microbiology and pharmacology, with the aim of linking a measure of drug exposure, relative to a measure of drug potency for the pathogen in question, to the microbiological or clinical effect achieved. The delineation of such relationships allows the drug dose to be chosen in a rational manner, so that the desired effect (for example, the maximal bactericidal effect) can be achieved in a large proportion of the intended patient population. Ultimately, the goal of any anti-infective therapy is to administer a dose of drug that has an acceptably high probability of achieving the desired therapeutic effect balanced with an acceptably low probability of toxicity. Appropriate use of the latest pharmacodynamic modelling approaches can minimize the emergence of resistance and optimize the outcome for patients.

Your institute does not have access to this article

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1: True between-patient variance.
Figure 2: Different pharmacodynamic variables are important for different drugs.
Figure 3: Only non-protein-bound drug is microbiologically active.
Figure 4: The higher the measure of potency, the lower the measure of drug exposure relative to the measure of potency.
Figure 5: The relationship between three pharmacodynamic parameters: peak concentration/MIC ratio, AUC/MIC ratio and time > MIC.
Figure 6: Suppressing the emergence of resistance.
Figure 7: Transferring to the clinic: linking the AUC/MIC ratio to clinical and microbiological outcomes.


  1. Preston, S. L. et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA 279, 125–129 (1998). The first prospective multicentre clinical trial recognized by the FDA as describing the development of a pharmacodynamic relationship for a clinical and microbiological outcome.

    CAS  Article  Google Scholar 

  2. Preston, S. L. et al. Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection. Antimicrob. Agents Chemother. 42, 1098–1104 (1998).

    CAS  Article  Google Scholar 

  3. Chien, S. -C. et al. Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses. Antimicrob. Agents Chemother. 41, 2256–2260 (1997).

    CAS  Article  Google Scholar 

  4. Eagle, H., Fleischman, R. & Levy, M. Continuous versus discontinuous therapy with penicillin: the effect of interval between injections on therapeutic efficacy. N. Engl. J. Med. 248, 481–488 (1953). The first animal infection study in which pharmacodynamic principles were used.

    CAS  Article  Google Scholar 

  5. Vogelman, B. et al. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J. Infect. Dis. 158, 831–847 (1988).

    CAS  Article  Google Scholar 

  6. Fluckiger, U., Segessenmann, C. & Gerber, A. U. Integration of pharmacokinetics and pharmacodynamics of imipenem in a human-adapted mouse model. Antimicrob. Agents Chemother. 35, 1905–1910 (1991).

    CAS  Article  Google Scholar 

  7. Craig, W. A., Redington, J. & Ebert, S. C. Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections. J. Antimicrob. Chemother. 27 (Suppl.) S29–S40 (1991).

    Article  Google Scholar 

  8. Andes, D. & Craig, W. A. Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models. Antimicrob. Agents Chemother. 46, 1665–1670 (2002).

    CAS  Article  Google Scholar 

  9. Craig, W. A. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26, 1–12 (1998). A summary of much early animal work in pharmacodynamics.

    CAS  Article  Google Scholar 

  10. Craig, W. A. Does the dose matter? Clin. Infect. Dis. 33, (Suppl.) S233–S237 (2001).

    CAS  Article  Google Scholar 

  11. Craig, W. A. Basic pharmacodynamics of antibacterials with clinical applications to the use of β-lactams, glycopeptides and linezolid. Infect. Dis. Clin. North Am. 17, 479–501 (2003).

    Article  Google Scholar 

  12. Eagle, H. & Musselman, A. D. The slow recovery of bacteria from the toxic effects of penicillin. J. Bacteriol. 58, 475–490 (1949).

    CAS  PubMed  PubMed Central  Google Scholar 

  13. Williamson, R. & Tomasz, A. Inhibition of cell wall synthesis and acylation of the penicillin binding proteins during prolonged exposure of growing Streptococcus pneumoniae to benzylpenicillin. Eur. J. Biochem. 151, 475–483 (1985).

    CAS  Article  Google Scholar 

  14. Odenholt-Tornqvist, I., Lowdin, E. & Cars, O. Pharmacodynamic effects of subinhibitory concentrations of β-lactam antibiotics in vitro. Antimicrob. Agents Chemother. 35, 1834–1839 (1991).

    CAS  Article  Google Scholar 

  15. Merriken, D. J., Briant, J. & Rolinson, G. N. Effect of protein binding on antibiotic activity in vivo. J. Antimicrob. Chemother. 11, 233–238 (1983).

    Article  Google Scholar 

  16. Bilello, J. A. et al. The uptake and anti-HIV activity of A-80987, an inhibitor of the HIV-1 protease, is reduced by human serum 1-acid glycoprotein. Antimicrob. Agents Chemother. 40, 1491–1497 (1996).

    CAS  Article  Google Scholar 

  17. Drusano, G. L., Johnson, D. E., Rosen, M. & Standiford, H. C. Pharmacodynamics of a fluoroquinolone antimicrobial in a neutropenic rat model of Pseudomonas sepsis. Antimicrob. Agents Chemother. 37, 483–490 (1993).

    CAS  Article  Google Scholar 

  18. Andes, D. & Craig, W. A. Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models. Antimicrob. Agents Chemother. 46, 1665–1670 (2002).

    CAS  Article  Google Scholar 

  19. US Food and Drug Administration. Meeting of the Food and Drug Administration Advisory Committee for the Division of Anti-Infective Drug Products. [online], <> (15 October 1998).

  20. Drusano, G. L. et al. Use of preclinical data for the choice of a Phase II/III dose for evernimicin with application to decision support for identification of a preclinical MIC breakpoint. Antimicrob. Agents Chemother. 45, 13–22 (2001). Describes the use of the Monte Carlo simulation as a method for evaluating the use of drug doses for populations and as a method for setting susceptibility breakpoints.

    CAS  Article  Google Scholar 

  21. Drusano, G. L. et al. Hollow fiber unit evaluation of a new human immunodeficiency virus (HIV)-1 protease inhibitor, BMS 232632, for determination of the linked pharmacodynamic variable. J. Infect. Dis. 183, 1126–1129 (2001).

    CAS  Article  Google Scholar 

  22. Drusano, G. L., Moore, K. H. P., Kleim, J. P., Prince, W. & Bye, A. Rational dose selection for a non-nucleoside reverse transcriptase inhibitor through the use of population pharmacokinetic modeling and Monte Carlo simulation. Antimicrob. Agents Chemother. 46, 913–916 (2002).

    CAS  Article  Google Scholar 

  23. Dudley, M. N. & Ambrose, P. G. Monte Carlo PK-PD simulation and new cefotaxime, ceftriaxone, and cefipime susceptibility breakpoints for S. pneumoniae, including strains with reduced susceptibility to penicillin. Abstract A-1263, 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California (2002).

  24. Ambrose, P. G., Craig, W. A., Bhavnani, B. M. & Dudley, M. N. Pharmacodynamic comparisons of different dosing regimens of penicillin G against penicillin-susceptible and -resistant pneumococci. Abstract A-635, 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California (2002).

  25. Jumbe, N. et al. Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. J. Clin. Invest. 112, 275–285 (2003). The first demonstration that it is possible to delineate a drug exposure that would prevent the amplification of mutant subpopulations, together with a prospective validation.

    CAS  Article  Google Scholar 

  26. Forrest, A. et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob. Agents Chemother. 37, 1073–1081 (1993).

    CAS  Article  Google Scholar 

  27. Feldman, C. et al. The presence and sequence of endotracheal tube colonization in patients undergoing mechanical ventilation. Eur. Resp. J. 13, 546–551 (1999).

    CAS  Article  Google Scholar 

  28. Friedland, D. R., Rothschild, M. A., Delgado, M., Isenberg, H. & Holzman, I. Bacterial colonization of endotracheal tubes in intubated neonates. Arch. Otolaryngol. Head Neck Surg. 127, 525–528 (2001).

    CAS  Article  Google Scholar 

  29. Tam, V. H., Preston, S. L. & Drusano, G. L. Optimal sampling schedule design for populations of patients. Antimicrob. Agents Chemother. 47, 2888–2891 (2003).

    CAS  Article  Google Scholar 

  30. Ambrose, P. G. et al. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob. Agents Chemother. 45, 2793–2797 (2001).

    CAS  Article  Google Scholar 

  31. Forrest, A., Chodosh, S., Amantea, M. A., Collins, D. A. & Schentag, J. J. Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis. J. Antimicrob. Chemother. 40 (Suppl.), A45–A57 (1997).

    Article  Google Scholar 

  32. Drusano, G. L. et al. The relationship between fluoroquinolone AUC/MIC ratio and the probability of eradication in patients with nosocomial pneumonia. J. Infect. Dis. (in the press).

  33. Kashuba, A. D., Nafziger, A. N., Drusano, G. L. & Bertino, J. S. Jr. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by Gram-negative bacteria. Antimicrob. Agents Chemother. 43, 623–629 (1999).

    CAS  Article  Google Scholar 

  34. Tam, V. H., McKinnon, P. S., Akins, R. L., Rybak, M. J. & Drusano, G. L. Pharmacodynamics of cefepime in patients with Gram-negative infections. J. Antimicrob. Chemother. 50, 425–428 (2002).

    CAS  Article  Google Scholar 

  35. Sheiner, L. B., Rosenberg, B. & Marathe, V. V. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J. Pharmacokinet. Biopharm. 5, 445–479 (1977).

    CAS  Article  Google Scholar 

  36. D'Argenio, D. Z. Optimal sampling times for pharmacokinetic experiments. J. Pharmacokinet. Biopharm. 9, 739–756 (1981).

    CAS  Article  Google Scholar 

  37. D'Argenio, D. Z. Incorporating prior parameter uncertainty in the design of sampling schedules for pharmacokinetic parameter estimation experiments. Math. Biosci. 99, 105–118 (1990).

    CAS  Article  Google Scholar 

  38. Tod, M. & Rocchisani, J. -M. Implementation of OSPOP, an algorithm for the estimation of optimal sampling times in pharmacokinetics by the ED, EID and API criteria. Comput. Methods Programs Biomed. 50, 13–22 (1996).

    CAS  Article  Google Scholar 

  39. Leary, R., Jelliffe, R., Schumitzky, A. & van Guilder, M. in Proceedings of the 14th IEEE Symposium on Computer-Based Medical Systems 389–394 (IEEE Computer Society, Bethesda, Maryland, July 2001).

    Google Scholar 

  40. Mallet, A., Mentre, F., Steimer, J. L. & Lokiec, F. Non-parametric maximum likelihood estimation for population pharmacokinetics, with application to cyclosporine. J. Pharmacokinet. Biopharm. 16, 311–327 (1988).

    CAS  Article  Google Scholar 

  41. Chow, A. T. et al. Safety and pharmacokinetics of multiple 750-milligram doses of intravenous levofloxacin in healthy volunteers. Antimicrob. Agents Chemother. 45, 2122–2125 (2001).

    CAS  Article  Google Scholar 

  42. Sheiner, L. B., Beal, S., Rosenberg, B. & Marathe, V. V. Forecasting individual pharmacokinetics. Clin. Pharmacol. Ther. 26, 294–305 (1979).

    CAS  Article  Google Scholar 

  43. Drusano, G. L. et al. Factors influencing the emergence of resistance to indinavir: role of virologic, immunologic, and pharmacologic variables. J. Infect. Dis. 178, 360–367 (1998).

    CAS  Article  Google Scholar 

  44. Drusano, G. L. et al. Relationship between foscarnet exposure, baseline cytomegalovirus blood culture and the time to progression of cytomegalovirus retinitis in HIV-positive patients. AIDS 10, 1113–1119 (1996).

    CAS  PubMed  Google Scholar 

  45. Craig, W. A. & Ebert, S. C. Continuous infusion of β-lactam antibiotics. Antimicrob. Agents Chemother. 36, 2577–2583 (1992).

    CAS  Article  Google Scholar 

  46. Drusano, G. L. Prevention of resistance: a goal for dose selection for antimicrobial agents. Clin. Infect. Dis. 36 (Suppl.) S42–S50 (2003).

    CAS  Article  Google Scholar 

  47. Mouton, J. W., Dudley, M. N., Cars, O., Derendorf, H. & Drusano, G. L. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs. Int. J. Antimicrob. Agents 19, 355–358 (2002).

    CAS  Article  Google Scholar 

Download references


The author benefitted from insightful discussions with F. Bloom.

Author information

Authors and Affiliations


Ethics declarations

Competing interests

The author declares no competing financial interests.

Related links

Related links



Pseudomonas aeruginosa

Staphylococcus aureus

Streptococcus pneumoniae


European Agency for the Evaluation of Medicinal Products

International Society of Anti-infective Pharmacology

Molecular Monte Carlo Home Page

Ordway Research Institute

US Food and Drug Administration



The study of the biochemical and physiological effects of drugs and the mechanisms of their actions.


(MIC). The lowest drug concentration that results in stasis.


(EC90). Usually applied to virus susceptibility — the drug concentration resulting in a decrease in replication of 90%.


The study of the bodily absorption, distribution, metabolism and excretion of drugs.


The volume of plasma that is completely cleared of drug per unit time.


The apparent volume in the patient relating dose and observed plasma concentration.


(AUC). A measure of the total exposure to drug — the integral of the concentration–time curve.


The highest concentration attained in a dosing interval.


The time that drug concentrations exceed the MIC, often stated as a percentage of the dosing interval.


An antibiotic that inhibits the growth of a bacterial population.


An antibiotic that kills 99.99% of a bacterial population.


Ratio of the area under the concentration–time curve to the MIC.


(PAE). Persistent inhibitory effect on a microorganism that results from drug exposure after the drug has been completely removed.


(PA-SME). Persistent inhibitory effect on a microorganism that results from drug exposure after the drug has been diluted to a fraction of the MIC.


(PD50 or CD50). The drug dose resulting in protection of 50% of challenged animals.


The ratio of the peak concentration to the MIC.


A blood disorder that is characterized by a severe reduction in the number of granulocytes in blood.


An abnormal decrease in the number of white cells in the blood.


An analytical technique for solving a problem by performing a large number of simulations and inferring a solution from the collective results that can be used to calculate the probability distribution of possible outcomes.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Drusano, G. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. Nat Rev Microbiol 2, 289–300 (2004).

Download citation

  • Issue Date:

  • DOI:

Further reading


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing